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Abstract
Background: Few biological markers are associated with survival after relapse of B-cell precursor acute lymphoblastic
leukemia (BCP-ALL). In pediatric T-cell ALL, we have identified promoter-associated methylation alterations that correlate
with prognosis. Here, the prognostic relevance of CpG island methylation phenotype (CIMP) classification was
investigated in pediatric BCP-ALL patients.
Methods: Six hundred and one BCP-ALL samples from Nordic pediatric patients (age 1–18) were CIMP classified at initial
diagnosis and analyzed in relation to clinical data.
Results: Among the 137 patients that later relapsed, patients with a CIMP− profile (n = 42) at initial diagnosis had an
inferior overall survival (pOS5years 33%) compared to CIMP+ patients (n = 95, pOS5years 65%) (p = 0.001), which remained
significant in a Cox proportional hazards model including previously defined risk factors.
Conclusion: CIMP classification is a strong candidate for improved risk stratification of relapsed BCP-ALL.
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Introduction
Using modern contemporary chemotherapy protocols for
childhood acute lymphoblastic leukemia (ALL) with treat-
ment stratification based on cytogenetic features, immu-
nophenotype and early response through quantification of
minimal residual disease, the 5-year overall survival now
exceeds 90% [1]. Despite improved results of primary
treatment, relapse is still the most common consequence
from treatment failure, and less progress has been
achieved for therapy outcome after relapse with an overall
survival rate of ≈ 55% in the Nordic countries [2]. Few
well-defined risk factors apart from time to relapse exist at
relapse, which impedes risk stratification after relapse.
DNA methylation is a central epigenetic mechanism
and an increasing body of evidence highlights the
importance of epigenetics in cancer biology [3]. Pediatric
ALL has been extensively characterized from a DNA
methylation perspective, and the methylation pattern
has been shown to reflect both cytogenetic aberrations
and immunophenotype [4]. We have previously shown
prognostic relevance of promoter associated DNA
methylation in T-cell acute lymphoblastic leukemia (T-
ALL), where patients displaying a less methylated CpG
island methylator phenotype (CIMP−) profile, based on
a defined set of CpG sites, were associated with worse
prognosis than patients exhibiting a more methylated
CIMP+ profile [5]. This finding was subsequently
validated in a recent Nordic cohort of high-risk T-ALL
patients (MRD > 0.1% at day 29) [6].
Several studies have attempted to ascertain prognostic
relevance from DNA methylation status at diagnosis
from B-cell precursor acute lymphoblastic leukemia
(BCP-ALL) patients [7, 8]. The overlap of prognostically
relevant signatures in BCP-ALL thus far is low, probably
due to the influence on cytogenetic alterations on
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epigenetic signatures [8]. However, a general finding
from these studies is that when patients are dichoto-
mized based on DNA methylation status, a worse out-
come is observed in the group with lower DNA
methylation levels [7, 8].
In the present study, we aimed to specifically investigate
if the T-ALL trained CIMP profile also holds prognostic
relevance in BCP-ALL, potentially giving a broader clinical
relevance of the CIMP profile in acute lymphoblastic
leukemia in general. We used genome-wide DNA methy-
lation data from a large, well-characterized cohort of
BCP-ALL patients, to evaluate the prognostic relevance of
CIMP classification at diagnosis and relapse.
Materials and methods
This study included 601 well-characterized diagnostic
and 23 relapse pediatric BCP-ALL samples from
children (1–18 years) diagnosed in the Nordic countries
(1996–2008) and treated according to the NOPHO ALL
1992 and 2000 protocols [1]. DNA methylation data
from previously published Illumina HumanMethyla-
tion450K arrays (Gene Expression Omnibus repository
accession number GSE49031) [8] were used to classify
the BCP-ALL samples as CIMP+ or CIMP− based on
percentage of methylated CpG sites within the 1293
CpG site CIMP panel, originally defined in T-ALL
datasets [5, 6]. Approximately, 2/3 of the CpG sites in
the CIMP panel were relevant for BCP-ALL, and there-
fore the percentage of methylated CpG sites within the
panel separating the CIMP +/− subgroups was adjusted
for the BCP-ALL samples to > 25% and ≤ 25%, respect-
ively (Additional file 1: Figure S1). CIMP classification
was verified in DNA extracted from 15 patients by a six-
gene high-resolution melting (HRM) curve gene panel
(Additional file 1: Figure S2). Detailed description of ma-
terials and methods are provided in the Additional file 1.
Results and discussion
The 601 diagnostic pediatric BCP-ALL samples were
classified based on their DNA methylation phenotype (n
= 175 CIMP− and n = 426 CIMP+) and analyzed in
relation to clinical characteristics. The cytogenetic aber-
rations were non-randomly distributed among the CIMP
subgroups at diagnosis (p < 0.001) (Additional file 1:
Table S1). The CIMP+ group was enriched for favorable
cytogenetic subtypes, i.e., t(12;21)/ETV6-RUNX1 (88%
CIMP+) and HeH (63% CIMP+), whilst the CIMP− group
was enriched for patients with unfavorable cytogenetics,
i.e., t(1;19)/TCF3-PBX1 (83% CIMP−) and t(9;22)/BCR-
ABL1 (67% CIMP−) subtypes (Additional file 1: Table S1).
The overall survival was significantly lower in the CIMP−
group compared with the CIMP+ group (pOS5years 85% vs
92%, p = 0.019, Fig. 1a), but CIMP status at initial diagno-
sis of ALL was not associated with relapse (p = 0.520) or
event-free survival (p = 0.424) (Additional file 1: Table S1).
The fact that CIMP status did not predict pCIR5years, but
showed differences in pOS5years indicates differences in re-
sponse to relapse treatment between the CIMP groups.
Thus, we further analyzed all the relapsed cases in our
cohort separately (n = 137), of which 42 were classified
as CIMP− and 95 as CIMP+ at initial diagnosis. Patients
in the CIMP subgroups did not differ with regard to sex,
age, or white blood cell counts at primary diagnosis, but
there was a higher frequency of unfavorable cytogenetic
subtypes within the CIMP− group (Table 1, p = 0.021).
The prognostic relevance of CIMP status at primary
diagnosis was analyzed in relation to overall survival
after relapse. The CIMP− subgroup had a significantly
worse prognosis with an pOS5years of 33% after relapse,
as compared with 65% for the CIMP+ subgroup (p =
0.001) (Table 1, Fig. 1b). In line with our results,
previous studies in this and other cohorts have shown a
similar trend in inferior clinical outcomes in BCP-ALL
patients with less methylated phenotypes at diagnosis
[7–9]. However, to our knowledge, no other study has
demonstrated that this difference may be explained by
outcome after relapse.
To further investigate the prognostic relevance of
CIMP status at primary diagnosis for survival after re-
lapse, we integrated previously identified clinical factors
of relevance for relapse outcome. Even though current
ALL relapse protocols do not include cytogenetic aberra-
tions in risk stratification, we and others have shown
that high risk genetic aberrations at diagnosis have
prognostic significance even at relapse [2, 10, 11]. Initial
risk group classification at primary diagnosis is based on
age at diagnosis, immunophenotype, cytogenetic
aberrations, WBC, and CNS involvement (Fig. 1c) [12].
After relapse, patients initially classified and treated as
standard risk/intermediate risk (SR/IR) had an pOS5years
of 63%, in contrast to 42% in the high risk (HR) group
(p = 0.008). CIMP status could further separate the
prognosis in these groups, with worse prognosis for
CIMP- patients (p = 0.002, log-rank adjusted for initial
risk group). The CIMP+/SR/IR patients had an pOS5years
of 69% after relapse compared to 45% for SR/IR CIMP−
patients (p = 0.06) (Fig. 1c). This disparity was even more
pronounced in the HR group, where patients classified
as CIMP+ at diagnosis had an pOS5years of 56% after
relapse compared with only 21% for HR/CIMP− patients
(p = 0.016) (Fig. 1c). These results demonstrate that by
combining initial risk group and CIMP status at diagno-
sis, the patients with poorest prognosis after relapse can
be further stratified.
Hematopoietic stem cell transplantation (HSCT) treat-
ment might influence the OS, but the outcome depends
on initial risk group at primary diagnosis, with improved
OS in high-risk patients allocated for HSCT [2]. In our
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cohort, the proportion of HSCT-treated patients after
relapse was similar in both of the CIMP groups
(Table 1). However, CIMP- status at diagnosis was as-
sociated with poorer outcome regardless if patients
were allocated to HSCT or not (p = 0.001, log-rank
adjusted for HSCT) (Fig. 1d).
Time in first complete remission and anatomic site of
relapse are two of the most important prognostic factors
in relapsed ALL and represent main stratifying factors
for relapse therapy [2, 13]. Expectedly, very early relapse
(< 18 months from primary diagnosis) had the worst
outcome in our cohort followed by early relapse (≥
18 months from diagnosis to < 6 months after comple-
tion of primary therapy) and late relapse (≥ 6 month
after completion of primary therapy) with a pOS5years at
26, 46, and 77%, respectively. The median time to re-
lapse did not differ significantly between the CIMP
groups, although there was a tendency towards relapse
sites. Isolated bone marrow relapse was more common
among CIMP− patients: 74% (31/42) vs 53% (50/95) in
the CIMP+ group (Table 1), but the difference did not
reach statistical significance (p = 0.077).
Finally, we assigned relapse risk groups based on a
combination of anatomical site of relapse and time to re-
lapse from initial primary diagnosis, as defined by the
International Study for Treatment of Childhood Relapse
ALL (IntReALL) into standard risk (late relapse and
early not isolated bone marrow iBM) or high risk (early
iBM and very early relapse) groups [2]. We found signifi-
cantly higher proportions (50 vs. 29%) of high risk char-
acteristics in the CIMP− patients compared with CIMP+
patients (p = 0.021) (Table 1). Importantly, CIMP status
at diagnosis could separate the prognosis in these risk
groups (p = 0.014, log-rank adjusted for combined site/
time risk classification), particularly in the high-risk
group (p = 0.023) (Fig. 1e).
We included CIMP status, age, sex, initial risk group
at diagnosis, HSCT status, and IntReALL risk classifica-
tion in a Cox proportional hazards regression analysis
for overall survival analysis after relapse. Although the
current IntReALL relapse risk grouping (p < 0.001, haz-
ard ratio (HR) high risk 3.79) holds the strongest prog-
nostic information, CIMP status at diagnosis (p = 0.036,
CIMP− HR 1.81) remained a significant prognostic
marker for survival at relapse (Table 2). Notably, when
including only IntReALL relapse risk class and CIMP
(See figure on previous page.)
Fig. 1 Kaplan-Meier overall survival analysis based on CIMP subgroups in BCP-ALL. Overall survival analysis in a 601 diagnostic BCP-ALL samples
CIMP classified at diagnosis. Follow-up time (months) from diagnosis to last follow-up. b–e One hundred and thirty-seven relapsed BCP-ALL samples
CIMP classified at diagnosis and stratified for c initial risk-group at primary diagnosis (SR/IR and HR), based on age at diagnosis, immunophenotype,
cytogenetic aberrations, WBC, and CNS involvement. d Hematopoietic stem cell transplantation after relapse (yes/no). e IntReALL (International Study
for Treatment of Childhood Relapse ALL) risk class (SR/HR) at relapse, based on site of relapse and time from diagnosis to relapse. Follow–up time
(months) from relapse to last follow up (b–e)
Table 1 Clinical characteristics of 137 relapsed pediatric
BCP-ALL patients that were CIMP classified at ALL diagnosis
Relapsed BCP-ALL patients CIMP−
n = 42
CIMP+
n = 95
p value
Sex male/female 28/14 51/44 ns
Age at primary diagnosis (months) 48 70 ns
(median, range) (16–185) (12–211)
WBC × 109/l at primary diagnosis 20,7 18,6 ns
(median, range) (2,2–269) (1,3–274)
Cytogenetics at primary diagnosis 0.021
Favorablea 18 (43%) 50 (53%)
Unfavorableb 11 (26%) 8 (8%)
Otherc 13 (31%) 37 (39%)
Initial risk group at primary diagnosisd ns
SR/IR 23 (55%) 64 (67%)
HR 19 (45%) 31 (33%)
Relapse sitee 0.077
Bone marrow isolated (iBM) 31 (74%) 50 (53%)
Combined (iBM and iEM) 6 (14%) 24 (26%)
Extramedullary (iEM) 5 (12%) 20 (21%)
Time to relapse (median, months) 29,5 35 ns
(Range) (5–124) (1–172)
Very early (VE) 11 (26%) 12 (13%)
Early (E) 16 (38%) 38 (40%)
Late (L) 15 (36%) 45 (47%)
IntReALL risk class at relapse
(relapse site/time to relapse)
0.021
Standard risk (L-iBM, iEM,
Comb, E-iEM, Comb)
21 (50%) 67 (71%)
High risk (VE-iBM, iEM,
Comb, E-iBM)
21 (50%) 28 (29%)
HSCT after relapse ns
Yes 15 (36%) 43 (45%)
No 27 (64%) 52 (55%)
pOS5years 0.33+/−0.08 0.65+/−0.05 0.001
ns not significant, WBC white blood cell count, SR/IR standard risk/
intermediate risk, HR high risk, HSCT hematopoietic stem
cell transplantation
aFavorable: t(12;21)(p12;q22), high hyperdiploidy (modal
chromosome number ≥ 50)
bUnfavorable: t(9;22)(q34;q11), t(1;19), MLL rearrangements (11q23),
hypodiploidy (modal chromosome number < 45)
cOther: non-stratifying or nonspecific cytogenetic aberrations
dDescribed in ref. [12]
eOne patient data missing
Borssén et al. Clinical Epigenetics  (2018) 10:31 Page 4 of 7
status at diagnosis in the Cox regression analysis, both
factors were prognostically relevant for survival after re-
lapse; IntReALL relapse risk class (p < 0.001, high risk
HR 3.27) and CIMP status (p = 0.011, CIMP− HR 1.99)
(Additional file 1: Table S3). This further indicates that
CIMP status at diagnosis holds important molecular
phenotype information of the leukemic cells of relevance
for prognosis after relapse.
In order to investigate the concordance in CIMP status
between diagnosis and relapse samples we compared
CIMP status in 23 paired samples from patients with
available DNA at both time points. This analysis showed
an increased percentage of methylated CpG sites in the
CIMP panel at relapse compared to at diagnosis (median
39 vs 57%, p < 0.001, Fig. 2a). This was expected since ac-
cumulated hypermethylation as a consequence of prolifer-
ation has been observed in this material as the relapsed
clone(s) have likely undergone additional replication since
diagnosis [8]. Importantly, although CIMP methylation
increased at relapse, CIMP status at diagnosis was highly
correlated CIMP status in the relapsed ALL cells (Spear-
man’s rho 0.825, p < 0.001, Fig. 2b). Thus, justifying
measuring CIMP status at diagnosis. Although clonal se-
lection may occur at relapse, this data supports similar
epigenetic characteristics based on CIMP status at diagno-
sis and relapse.
The observation that our CIMP profile adds prognostic
information among relapsed BCP-ALL patients and high-
risk (MRD > 0.1% at treatment day 29) T-ALL patients [6]
makes our panel a potentially useful prognostic marker
for high-risk ALL patients that today lack biological
therapy stratifying markers. Therefore, upfront methyla-
tion array analysis at diagnosis could be implemented to
add epigenetic phenotype information (CIMP status) with
potential prognostic relevance, in addition, as a comple-
mentary method to support prediction of cytogenetic
subtypes [14]. Whether the prognostic relevance of CIMP
classification in BCP-ALL could be further improved by
including MRD status could not be addressed here since
MRD data was not available for the majority of patients,
and hence remains to be evaluated in replicative studies of
patients treated by contemporary protocols [15].
The biological mechanisms, i.e., genetic aberrations in
DNA methylation associated genes or oncogenes remain
Table 2 Cox’s proportional hazard regression analysis of risk factors for overall survival in relapse patients
Risk factor N Reference group HR
CIMP (−/+) (42/95) CIMP+ 1.81 (1.04–3.16) (*p = 0.036)
Sex (male/female) (79/58) Sex = female 0.95 (0.56–1.60)
Age at primary diagnosis (years) (137) 1.04 (0.97–1.10)
Initial risk group at primary diagnosis (SR/IR and HR) (87/50) Risk group = SR/IR 0.96 (0.53–1.76)
HSCT after relapse (no/yes) (79/58) HSCT = no 0.55 (0.32–0.97) (*p = 0.040)
IntReALL risk class (relapse site/time to relapse (SR/HR)) (88/49) Risk group = SR 3.79 (1.98–7.29) (*p < 0.001)
Fig. 2 CIMP methylation in paired diagnosis-relapse samples from BCP-patients. a CIMP methylation percentage in 23 paired diagnostic and
relapse samples from BCP-ALL patients. Mean values at diagnosis and relapse were compared by paired samples t test. b Scatter plot showing
spearman’s rho correlation between CIMP methylation percentage at diagnosis and relapse in 23 BCP-ALL patients
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to be investigated in relation to CIMP status in ALL.
Several mechanisms have been shown to influence the
epigenetic landscape of ALL cells and recurrent
mutations in genes involved in epigenetic regulation
have been reported [16, 17]. In a previous analysis of the
genes associated with the CpG sites in our CIMP panel,
an overrepresentation of transcription factors and poly-
comb repressive complex target genes was shown [5].
The genes in the CIMP panel were associated with
cAMP signaling, but the functional relevance of these
associations remains to be shown [5]. Future studies will
be needed further evaluate the biology underlying CIMP
subgroups.
To conclude, this study together with our recently
published study on T-ALL [6] indicates that CIMP
classification has the potential to separate high-risk
pediatric ALL patients and may confer important infor-
mation in clinical treatment decision-making.
Additional file
Additional file 1: Methods description, figures, and tables can be found
at the Clinical Epigenetics webpage. (DOCX 282 kb)
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